OX40+ T Lymphocytes and IFN-γ Are Associated with American Tegumentary Leishmaniasis Pathogenesis

Overview

Journal An Bras Dermatol

Specialty Dermatology

Date 2012 Dec 1

PMID 23197203

Authors

Patricia Luciana Batista Domingos

Agostinho Goncalves Viana

Carlos Alberto de Carvalho Fraga

Paulo Rogerio Ferreti Bonan

Affiliations

Soon will be listed here.

Abstract

Background: Leishmaniases are zoonoses considered a public health problem, representing a complex group of diseases with a broad clinical spectrum and epidemiological diversity. Leishmaniasis is caused by several species of protozoa of the genus Leishmania. The evolution of the pathology and the resolution of the leishmaniasis are dependent mainly on the Leishmania species involved, although the cytokine profile plays an important role in the development of the immune response.

Objectives: The purpose of our study was to evaluate the immune response of patients affected by lesions of cutaneous leishmaniasis by immunostaining of the OX40, CD20, IFN-γ and IL-4 proteins.

Methods: The tissue samples were collected from indolent skin ulcers confirmed as cutaneous leishmaniasis of 41 patients aged between six and 90 years. The lesions were submitted to OX40, CD20, INF-γ and IL-4 immunolabeling.

Results: We observed a statistically significant higher expression of IFN-γ compared with IL-4 (p=0.009). Besides, OX40 had higher expression when compared with CD20 (p<0.001).

Conclusion: The present study indicates that the immune response in lesions of cutaneous leishmaniasis is associated with a healing process, which can be explained by the higher expression of IFN-γ when compared with IL4 protein levels.

References

Sacks D, Noben-Trauth N . The immunology of susceptibility and resistance to Leishmania major in mice. Nat Rev Immunol. 2002; 2(11):845-58. DOI: 10.1038/nri933. View

Bertram E, Dawicki W, Watts T . Role of T cell costimulation in anti-viral immunity. Semin Immunol. 2004; 16(3):185-96. DOI: 10.1016/j.smim.2004.02.006. View

de Souza-Neto S, Carneiro C, Vieira L, Afonso L . Leishmania braziliensis: partial control of experimental infection by interleukin-12 p40 deficient mice. Mem Inst Oswaldo Cruz. 2004; 99(3):289-94. DOI: 10.1590/s0074-02762004000300009. View

Wojciechowski W, Li H, Marshall S, Dellagnola C, Espinoza-Delgado I . Enhanced expression of CD20 in human tumor B cells is controlled through ERK-dependent mechanisms. J Immunol. 2005; 174(12):7859-68. DOI: 10.4049/jimmunol.174.12.7859. View

Gomes-Silva A, de Cassia Bittar R, Dos Santos Nogueira R, Amato V, da Silva Mattos M, Oliveira-Neto M . Can interferon-gamma and interleukin-10 balance be associated with severity of human Leishmania (Viannia) braziliensis infection?. Clin Exp Immunol. 2007; 149(3):440-4. PMC: 2219325. DOI: 10.1111/j.1365-2249.2007.03436.x. View

Castellano L, Correia Filho D, Argiro L, Dessein H, Prata A, Dessein A . Th1/Th2 immune responses are associated with active cutaneous leishmaniasis and clinical cure is associated with strong interferon-gamma production. Hum Immunol. 2009; 70(6):383-90. DOI: 10.1016/j.humimm.2009.01.007. View

Schroder K, Hertzog P, Ravasi T, Hume D . Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol. 2003; 75(2):163-89. DOI: 10.1189/jlb.0603252. View

Bogdan C, Rollinghoff M, Diefenbach A . The role of nitric oxide in innate immunity. Immunol Rev. 2000; 173:17-26. DOI: 10.1034/j.1600-065x.2000.917307.x. View

Lobo I, Soares M, Correia T, de Freitas L, Oliveira M, Nakatani M . Heat therapy for cutaneous leishmaniasis elicits a systemic cytokine response similar to that of antimonial (Glucantime) therapy. Trans R Soc Trop Med Hyg. 2005; 100(7):642-9. DOI: 10.1016/j.trstmh.2005.08.011. View

10.

Rassidakis G, Medeiros L, Viviani S, Bonfante V, Vassilakopoulos T, Mesina O . CD20 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin's disease: associations with presenting features and clinical outcome. J Clin Oncol. 2002; 20(5):1278-87. DOI: 10.1200/JCO.2002.20.5.1278. View

11.

Venugopal P, Sivaraman S, Huang X, Nayini J, Gregory S, Preisler H . Effects of cytokines on CD20 antigen expression on tumor cells from patients with chronic lymphocytic leukemia. Leuk Res. 2000; 24(5):411-5. DOI: 10.1016/s0145-2126(99)00206-4. View

12.

Salek-Ardakani S, Croft M . Regulation of CD4 T cell memory by OX40 (CD134). Vaccine. 2005; 24(7):872-83. DOI: 10.1016/j.vaccine.2005.07.108. View

13.

Venugopal P, LESLIE W, OBrien T, Gregory S . CD20-negative relapse after (131)I-anti-CD20 therapy. J Clin Oncol. 1999; 17(11):3692-3. DOI: 10.1200/JCO.1999.17.11.3692. View

14.

Reis L, Brito M, Souza M, Medeiros A, Silva C, Luna C . Cellular immune response profile in patients with American tegumentary leishmaniasis prior and post chemotherapy treatment. J Clin Lab Anal. 2009; 23(1):63-9. PMC: 6649044. DOI: 10.1002/jcla.20291. View

15.

Turpaev K . Reactive oxygen species and regulation of gene expression. Biochemistry (Mosc). 2002; 67(3):281-92. DOI: 10.1023/a:1014819832003. View

16.

Portlock C, Donnelly G, Qin J, Straus D, Yahalom J, Zelenetz A . Adverse prognostic significance of CD20 positive Reed-Sternberg cells in classical Hodgkin's disease. Br J Haematol. 2004; 125(6):701-8. DOI: 10.1111/j.1365-2141.2004.04964.x. View

17.

Redmond W, Weinberg A . Targeting OX40 and OX40L for the treatment of autoimmunity and cancer. Crit Rev Immunol. 2008; 27(5):415-36. DOI: 10.1615/critrevimmunol.v27.i5.20. View

18.

Alexander J, Bryson K . T helper (h)1/Th2 and Leishmania: paradox rather than paradigm. Immunol Lett. 2005; 99(1):17-23. DOI: 10.1016/j.imlet.2005.01.009. View

19.

Eisenberg R, Looney R . The therapeutic potential of anti-CD20 "what do B-cells do?". Clin Immunol. 2005; 117(3):207-13. DOI: 10.1016/j.clim.2005.08.006. View

20.

Tedder T, Engel P . CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol Today. 1994; 15(9):450-4. DOI: 10.1016/0167-5699(94)90276-3. View